REVEAL 2.0 Risk Score for Pulmonary Arterial Hypertension
Predicts 1-year survival in pulmonary arterial hypertension (PAH) using clinical, haemodynamic, and echocardiographic parameters.
Score interpretation
REVEAL 2.0 ≤ 6: 1-year survival > 90%. Low-risk PAH.
→ Continue and optimise PAH therapies. Annual reassessment.
REVEAL 2.0 7–8: 1-year survival 85–90%.
→ Consider escalating to combination PAH therapy. Close monitoring every 3–6 months.
REVEAL 2.0 9–10: 1-year survival 70–85%.
→ Escalate therapy. Consider IV prostacyclin. Transplant assessment referral.
REVEAL 2.0 ≥ 11: 1-year survival < 70%. High risk.
→ Urgent therapy escalation. Lung transplant evaluation. Goals-of-care discussion.
Interpretation bands for the REVEAL 2.0. Apply clinical judgement and local guidance.
References
- Benza RL et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights from the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation. 2010;122(2):164-172.
Related
Curated clinical cross-links plus same-class fallbacks.
- Selexipag · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
- Sildenafil · PDE5 Inhibitor — Pulmonary Arterial Hypertension
- Bosentan · Endothelin Receptor Antagonist — Pulmonary Arterial Hypertension
- Ambrisentan · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.